Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One cycle Clear all
Completed Phase 2 Interventional Results available

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

NCT00305682
View directory record Official record
Conditions
Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, Fludarabine, mycophenolate mofetil, umbilical cord blood transplantation, total body irradiation, Sirolimus
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 1 Interventional

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

NCT00556088
View directory record Official record
Conditions
Solid Tumors
Interventions
LBH589, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 3 Interventional

Early Amiodarone in Shockable Cardiac Arrest

NCT06680869
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Amiodarone Hydrochloride Injection, Usual Care Protocol
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Terminated Phase 1 Interventional

OSI-906 and Irinotecan in Patients With Advanced Cancer

NCT01016860
View directory record Official record
Conditions
Colorectal Cancer
Interventions
OSI-906, irinotecan
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional Results available

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

NCT00425503
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
PS-341 (bortezomib)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 1 Interventional

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

NCT04053283
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

NCT00263341
View directory record Official record
Conditions
Contraception
Interventions
NES/EE CVR
Combination Product
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 3 Interventional

Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial

NCT00731627
View directory record Official record
Conditions
Subarachnoid Haemorrhage
Interventions
placebo, simvastatin
Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 4 Interventional Results available

Desensitization in Kidney Transplantation

NCT00908583
View directory record Official record
Conditions
HLA Sensitization
Interventions
plasmapheresis, Bortezomib, Rituximab, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 23, 2026, 3:29 PM EDT
Not listed Phase 2Phase 3 Interventional

Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)

NCT01065870
View directory record Official record
Conditions
Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
Interventions
Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 23, 2026, 3:29 PM EDT
Terminated Phase 1 Interventional

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

NCT02818023
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vemurafenib, Cobimetinib
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 1 Interventional

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

NCT02077933
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Kidney Neoplasms, Pancreatic Neuroendocine Neoplasms (pNETs)
Interventions
alpelisib, everolimus, exemestane
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Fayetteville, Arkansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 2 Interventional

MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes

NCT06930638
View directory record Official record
Conditions
Stroke
Interventions
Ischemic Conditioning, Antioxidant Supplement
Device · Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

NCT06843447
View directory record Official record
Conditions
Ovarian Cancer Recurrent
Interventions
Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

NCT03909152
View directory record Official record
Conditions
Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer
Interventions
Onapristone ER, Onapristone ER + Anastrozole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Active, not recruiting Phase 3 Interventional

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions
Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
47
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 23, 2026, 3:29 PM EDT
Terminated Phase 2 Interventional Results available

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

NCT00379197
View directory record Official record
Conditions
Breast Cancer
Interventions
naltrexone, PET scan
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 3:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Physician Coaching to Reduce Opioid-related Harms

NCT02433496
View directory record Official record
Conditions
Substance Abuse, Chronic Pain
Interventions
Physician coaching
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
53,132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 23, 2026, 3:29 PM EDT
Not yet recruiting Phase 2 Interventional

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

NCT07729046
View directory record Official record
Conditions
Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
Interventions
Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

NCT04837196
View directory record Official record
Conditions
Advanced Malignancies, Advanced Cancer
Interventions
ASP7517, Pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 23, 2026, 3:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

NCT03198026
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
Interventions
Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 3:29 PM EDT
Withdrawn Phase 4 Interventional

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

NCT01941134
View directory record Official record
Conditions
Bariatric Surgery Candidate, Contraception
Interventions
ethinyl estradiol-levonorgestrel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 23, 2026, 3:29 PM EDT
Completed Phase 2 Interventional

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

NCT01146509
View directory record Official record
Conditions
Migraine Headache
Interventions
Aricept (donepezil hydrochloride)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 23, 2026, 3:29 PM EDT